Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

NHS National Pharmaceuticals Transition 2021_3

The NHS Commissioning Board (operating under the name of NHS England)

This public procurement record has 2 releases in its history.

Award

04 Nov 2021 at 14:00

Award Notice
Tender

02 Jun 2021 at 16:02

Tender Notice
Summary of the contracting process

The NHS Commissioning Board (operating under the name of NHS England) is currently conducting an open tender for the NHS National Pharmaceuticals Transition 2021_3. This procurement, classified under the pharmaceutical products category, is set in the UK and is aimed at supplying goods valued at approximately £214 million. The tender consists of several lots including oral products for all regions, hospital-only products for various regions (LSNE, NWLN, CESW), and transition products. Key dates are crucial, with the tender period concluding on 7th July 2021 and contract periods spanning from October 2021 through various endings depending on the lot. The contract may have options for extensions of up to 48 months at the discretion of the authority.

This procurement process offers significant opportunities for businesses engaged in pharmaceutical manufacturing and supply. Companies specialising in hospital products, oral pharmaceuticals, and related healthcare services can compete effectively for this contract. Established and emerging suppliers aiming to expand their footprint within public health sectors should consider participating, particularly as the framework agreement allows for a potentially expansive scope of business across multiple NHS bodies and local authorities. Interested parties should ensure compliance with the procurement requirements and be well-prepared for submission through the designated eTendering portal.

How relevant is this notice?

Notice Information

Notice Title

NHS National Pharmaceuticals Transition 2021_3

Notice Description

NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633

Lot Information

Hospital Only Products - CESW region

NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products:LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition:LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months)

Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.

Hospital Only Products - LSNE region

NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months) Additional information: Price is not the only award criterion and all criteria are stated only in the procurement documents

Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.

Hospital Only Products - NWLN region

NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months)

Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.

Oral (plus non-parenteral) products: All regions

NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months)

Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.

Transition Products - CESW region

NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months)

Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.

Transition Products - LSNE region

NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months)

Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.

Transition Products - NWLN region

NHS National Pharmaceuticals Transition 2021_3Offer reference number: CM/PHG/21/5633Period of framework agreement: Dates detailed below, with an option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.Potential periods of call-offs under the framework agreement:Oral (plus non-parenteral) Products: All regions: 01/10/2021 to 31/05/2024 (32 months)Hospital Only Products: LSNE: 01/10/2021 to 30/06/2022 (9 months)NWLN:01/10/2021 to 31/01/2023 (16 months)CESW:01/10/2021 to 30/09/2023 (24 months)Transition: LSNE: 26/10/2021 to 30/06/2022 (8 months)NWLN: 26/10/2021 to 31/01/2023 (15 months)CESW: 26/10/2021 to 30/09/2023 (23 months)

Options: option or options to extend (at the discretion of the Authority) up to maximum contract length of 48 months.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-02b7a6
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/027695-2021
Current Stage
Award
All Stages
Tender, Award

Procurement Classification

Notice Type
Tender Notice
Procurement Type
Framework
Procurement Category
Goods
Procurement Method
Open
Procurement Method Details
Open procedure
Tender Suitability
Not specified
Awardee Scale
Large, SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33600000 - Pharmaceutical products

Notice Value(s)

Tender Value
£214,113,004 £100M-£1B
Lots Value
Not specified
Awards Value
Not specified
Contracts Value
£1

Notice Dates

Publication Date
4 Nov 20214 years ago
Submission Deadline
7 Jul 2021Expired
Future Notice Date
Not specified
Award Date
14 Sep 20214 years ago
Contract Period
26 Oct 2021 - 30 Sep 2023 1-2 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Cancelled
Awards Status
Active
Contracts Status
Active

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
The NHS Commissioning Board (operating under the name of NHS England)
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
RUNCORN
Postcode
WA7 2ES
Postcode Area
Warrington
Country
England
Major Region (ITL 1)
TLD North West (England)
Basic Region (ITL 2)
TLD7 Merseyside
Small Region (ITL 3)
TLD71 East Merseyside
Delivery Location
Not specified
Local Authority
Halton
Electoral Ward
Halton Lea
Westminster Constituency
Runcorn and Helsby

Supplier Information

Number of Suppliers
36
Supplier Names

Accord-UK Ltd

Aguettant Ltd

Alturix

Amarox Limited

Ambe Medical Group Ltd

Aspen Pharmacare UK Limited

Aspire Pharma Limited

Brown and Burk UK Ltd

CST Pharma Limited

Cipla (EU) Ltd

Colonis Pharma Ltd

Consilient Health Ltd

Day Lewis Medical Ltd

Dr.Reddy's Laboratories (UK) Limited

Drugsrus Ltd

Glenmark Pharmaceuticals Europe Limited

Kensington Pharma Ltd

Kent Pharma Ltd

Laboratorio Reig Jofre SA

Lucane Pharma

Macure Pharma ApS

Mercury Pharmaceuticals Limited

Morningside Pharmaeuticals

Mylan

Napp Pharmaceuticals Ltd

Panpharma UK Limited

Pfizer Ltd

Ranbaxy UK

Roche Products Ltd

Seacross Pharmaceuticals Ltd

Teva UK Limited

Thornton and Ross Ltd

Torbay Pharmaceuticals

Wockhardt UK Limited

Zentiva Pharma UK Ltd

medac Pharma LLP

Further Information

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...